Article Details
Retrieved on: 2022-01-29 10:43:26
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The firm currently has an “underweight” rating on the pharmaceutical company's stock. Morgan Stanley's target price indicates a potential downside of ...
Article found on: etfdailynews.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here